Maintenance of Clinical Effect in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib, a Selective jak1 Inhibitor: Exploratory 20-Week Data Analysis of the Phase 2 Fitzroy Study
Journal of Crohns & Colitis(2017)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要